We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PD-L1 expression in papillary renal cell carcinoma.
- Authors
Takanobu Motoshima; Yoshihiro Komohara; Chaoya Ma; Arni Kusuma Dewi; Hirotsugu Noguchi; Sohsuke Yamada; Toshiyuki Nakayama; Shohei Kitada; Yoshiaki Kawano; Wataru Takahashi; Masaaki Sugimoto; Motohiro Takeya; Naohiro Fujimoto; Yoshinao Oda; Masatoshi Eto; Motoshima, Takanobu; Komohara, Yoshihiro; Ma, Chaoya; Dewi, Arni Kusuma; Noguchi, Hirotsugu
- Abstract
<bold>Background: </bold>The immune escape or tolerance of cancer cells is considered to be closely involved in cancer progression. Programmed death-1 (PD-1) is an inhibitory receptor expressed on activating T cells, and several types of cancer cells were found to express PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2).<bold>Methods: </bold>In the present study, we investigated PD-L1/2 expression in papillary renal cell carcinoma (pRCC).<bold>Result: </bold>We found PD-L1 expression in 29 of 102 cases, but no PD-L2 expression was seen. PD-L1 expression was not significantly correlated with any clinicopathological factor, including progression-free survival and overall survival. The frequency of PD-L1-positive cases was higher in type 2 (36%) than in type 1 (22%) pRCC; however, there was no significant difference in the percentages of score 0 cases (p value = 0.084 in Chi-square test). The frequency of high PD-L1 expression cases was higher in type 2 (23%) than in type 1 (11%), and the frequency of high PD-L1 expression cases was higher in grade 3/4 (21%) than in grade 1/2 (13%). However, no significant association was found between PD-L1 expression and all clinicopathological factors in pRCC.<bold>Conclusion: </bold>High expression of PD-L1 in cancer cells was potentially associated to highly histological grade of malignancy in pRCC. The evaluation of the PD-L1 protein might still be useful for predicting the efficacy of anti-cancer immunotherapy using immuno-checkpoint inhibitors, however, not be useful for predicting the clinical prognosis.
- Subjects
GENE expression; CANCER cells; CANCER invasiveness; T cells; LIGANDS (Biochemistry); IMMUNOTHERAPY; RENAL cell carcinoma; PROGRESSION-free survival; CANCER treatment; ANTIGENS; KIDNEY tumors; RETROSPECTIVE studies; DIAGNOSIS
- Publication
BMC Urology, 2017, Vol 17, p1
- ISSN
1471-2490
- Publication type
journal article
- DOI
10.1186/s12894-016-0195-x